# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Marie Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET013-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Adaeze Nwosu, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Hematology consultation for pancytopenia, with bone marrow aspirate and biopsy. **S**

## History of present illness

Madame Curie is seen in hematology one week after her primary care visit, where two months of fatigue, breathlessness on stairs, easy bruising, and a recent fever led to a blood count showing pancytopenia with a low reticulocyte count. She received two units of irradiated red cells that day. She is less breathless since the transfusion but still tires by midafternoon. New bruises appear on her arms and shins without injury; she has had no nosebleeds, gum bleeding, blood in the urine or stool, or further fever. She has worked for decades with radium sources and X-ray equipment, much of it before modern shielding, and she has stopped laboratory work since the last visit. She wants the data and the plan in detail. **S**

| Element | Detail |
|---|---|
| Since the transfusion | Less breathless; fatigue by midafternoon |
| Bleeding | Bruises on arms and shins without injury; no mucosal, urinary, or bowel bleeding |
| Infection | No fever since the first visit |
| Exposure | Decades of occupational ionizing radiation; no further exposure since the first visit |
| Patient preference | Wants the full data and plan |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue by midafternoon; no fever, night sweats, or weight loss |
| Hematologic | Positive | Easy bruising; no mucosal bleeding |
| Cardiovascular | Positive | Breathless on stairs, better since transfusion; no chest pain |
| Eyes | Positive | Glare and blurred reading vision in the right eye |
| Skin | Positive | Thin, scarred fingertips; no rash |

5 systems reviewed. **S**

## Current medications

- Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology **S**
- Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/70 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.9 °C; oxygen saturation 98% on room air; weight 51 kg; BMI 20.7 kg/m². All vital signs are synthetic.

Hemoglobin: 8.9 g/dL (low); White blood cell count: 1.8 10*3/uL (low); Absolute neutrophil count: 0.4 10*3/uL (low); Platelet count: 15 10*3/uL (low); MCV: 101 fL (high); Absolute reticulocyte count: 12 10*3/uL (low). All results are synthetic.

## Change since baseline

- Hemoglobin: 7.2 g/dL (low) at baseline, 8.9 g/dL (low) at this visit **S**
- White blood cell count: 1.9 10*3/uL (low) at baseline, 1.8 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.4 10*3/uL (low) at baseline, 0.4 10*3/uL (low) at this visit **S**
- Platelet count: 18 10*3/uL (low) at baseline, 15 10*3/uL (low) at this visit **S**
- MCV: 104 fL (high) at baseline, 101 fL (high) at this visit **S**
- Absolute reticulocyte count: 14 10*3/uL (low) at baseline, 12 10*3/uL (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Pale, alert, precise, and composed |
| Skin | Scattered bruises on the forearms and shins; a few petechiae on the lower legs; thin, scarred fingertip skin |
| Mouth | No gum bleeding or blood blisters; no ulcers |
| Lymph nodes | No lymphadenopathy |
| Abdomen | No hepatomegaly or splenomegaly |
| Heart | Regular rhythm, pulse 92; soft flow murmur |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe aplastic anemia, newly confirmed** (D61.2). Marrow cellularity about 10 percent with no dysplasia, fibrosis, or malignant cells; cytogenetics normal; no PNH clone. Neutrophils 0.4, platelets 15, and reticulocytes 12 thousand per microliter meet the criteria for severe, not very severe, aplastic anemia. Hemoglobin 8.9 g/dL after the transfusion. The radiation cause is probable but an immune mechanism cannot be excluded, so standard immunosuppression is chosen; transplant is not chosen at 66. **S**
   - Horse antithymocyte globulin as a four-day infusion course in the hematology unit, starting today.
   - Start cyclosporine (modified) 100 mg twice daily, with the dose adjusted to trough levels by hematology.
   - Start eltrombopag 150 mg once daily on an empty stomach.
   - Start acyclovir 400 mg twice daily as antiviral prophylaxis.
   - Irradiated, leukocyte-depleted blood products from now on; inactivated vaccines only.
2. **Occupational exposure to ionizing radiation** (Z57.1). Decades of exposure, recorded in her history; the link to her marrow failure is probable but not proven. **S**
   - No further radiation exposure while counts recover.
   - Occupational health review of shielding and dosimetry for her laboratory staff.
3. **Chronic radiodermatitis of the fingertips** (L58.1). Stable thin, scarred skin; no ulceration. **S**
   - Emollient and protection from injury while platelets are low.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CBC with differential and reticulocyte count | Weekly during the first months of treatment | Completed today | Before treatment: hemoglobin 8.9 g/dL after transfusion, white cells 1.8, neutrophils 0.4, platelets 15, reticulocytes 12 thousand per microliter, MCV 101 fL |
| Laboratory | Bone marrow aspirate and trephine biopsy with cytogenetics | At diagnosis | Completed today | About 10 percent cellularity; no dysplasia, fibrosis, or malignant cells; normal cytogenetics, excluding hypoplastic myelodysplasia |
| Laboratory | PNH clone by flow cytometry | At diagnosis | Completed today | No PNH clone |
| Laboratory | Kidney function and potassium before cyclosporine | Before starting | Up to date | One week ago: creatinine 0.78 mg/dL, eGFR 84, potassium 4.1 |
| Laboratory | Liver tests (ALT) before eltrombopag | Before starting | Deferred | No ALT is on record before eltrombopag started today; bilirubin was 0.6 mg/dL a week ago. A deviation from the protocol. Corrective action: ALT with the next blood draw |
| Laboratory | Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV) | At diagnosis, before immunosuppression | Deferred | No results are in this record before treatment started, a deviation from the protocol. Corrective action: flagged to hematology to send with the next blood draw |
| Laboratory | Cyclosporine trough level | Regularly from the first weeks of treatment, to guide the dose | Due | Cyclosporine starts today; first level due within the first weeks |
| Medication safety | Antiviral prophylaxis during immunosuppression | From the start of antithymocyte globulin | Completed today | Acyclovir 400 mg twice daily started |
| Medication safety | Antibacterial and antifungal prophylaxis while severely neutropenic | While neutrophils are below 0.5 thousand per microliter, by local policy | Deferred | Neutrophils 0.4. Not prescribed today; the guideline leaves agent and threshold to local policy. Recorded as a gap for hematology to confirm; same-day fever plan in place |
| Medication safety | Pneumocystis prophylaxis | Not routinely required with this regimen | Not indicated | Not started |
| Medication safety | Irradiated, leukocyte-depleted blood products | From antithymocyte globulin onward | Completed today | Blood bank flag placed |
| Examination | Blood pressure and weight on cyclosporine | Every visit | Completed today | 116/70 mmHg, weight 51 kg before cyclosporine |
| Self-management | Same-day assessment for a temperature of 38 °C or higher; bleeding precautions; no aspirin or NSAIDs | Every visit | Completed today | Written plan given; thermometer at home |
| Self-management | No further occupational radiation exposure | While counts recover | Completed today | Away from the laboratory since the first visit |
| Examination | Comprehensive dilated eye examination with functional vision assessment | Every 1 to 2 years at 65 or older, and when symptoms limit daily tasks | Due | Right-eye glare noted; review at the next primary care visit |

## Goal progress

- Hematology evaluation with bone marrow biopsy within one week of the pancytopenia result. Outcome by 2026-05-18: Seen and biopsied seven days after the first visit. **S**
- No serious infection or bleeding during the first months of treatment. In progress; target 2026-06-29. **S**
- Early rise in neutrophil and platelet counts by the six-week visit. In progress; target 2026-06-29. **S**
- Read standard print comfortably with the right eye after capsulotomy. In progress; target 2026-06-29. **S**

## Medication changes

- Started: Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology **S**
- Started: Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach **S**
- Started: Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression **S**

## Guideline basis

- Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (2024), British Society for Haematology (British Journal of Haematology)
- CMID: Clinical Monitoring Intelligence Database, anemia and cataract monographs (2026), Aether Forge

## Follow-up

- Antithymocyte globulin course in the hematology unit this week. Weekly blood counts. Primary care review in three weeks with blood counts, kidney function, potassium, ALT, and an eye review. **S**
- Next scheduled visit 2026-06-08: primary care follow-up three weeks after starting immunosuppressive therapy, with a cataract and eye review. **S**
